Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 93 results:
Author Title Type [ Year
] Filters: Author is Anastasilakis, Athanasios D [Clear All Filters]
(2016). Activin A and follistatin in patients with nonalcoholic fatty liver disease..
Metabolism. 65(10), 1550-8.
(2016). Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans..
Metabolism. 65(10), 1459-65.
(2016). Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease..
J Bone Miner Metab. 34(4), 447-56.
(2016). Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid..
J Clin Endocrinol Metab. 101(9), L89-90.
(2016). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2017). Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD.
Metabolism. 73, 1-8.
(2017). Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases..
J Bone Miner Res. 32(6), 1291-1296.
(2017). Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity..
Metabolism. 71, 198-201.
(2017). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2018). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2019). Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview..
Hormones (Athens). 18(1), 65-70.
(2019). Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society..
Bone. 127, 401-418.
(2019). Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass..
J Musculoskelet Neuronal Interact. 19(3), 253-257.
(2019). Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment..
Bone. 120, 44-49.
(2019). Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls..
Horm Metab Res. 51(2), 112-119.
(2019). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?.
Metabolism. 93, 100-102.
(2019). Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study..
Metabolism. 154005.
(2019). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019). Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD..
J Clin Endocrinol Metab.
(2020). Combination and sequential treatment in women with postmenopausal osteoporosis..
Expert Opin Pharmacother. 21(4), 477-490.
(2020). Obesity, osteoporosis and bone metabolism..
J Musculoskelet Neuronal Interact. 20(3), 372-381.
